We were delighted to talk with Dr Rolof Gijtenbeek (Medical Center Leeuwarden, Leeuwarden, The Netherlands) around his abstract on ‘Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.‘, (Presentation ID 4324) which was presented at ERS International Congress 2021, 5-8 September 2021.
- EGFR tyrosine kinase inhibitors such as erlotinib are indicated in the treatment of EGFR mutated non-small cell lung cancer (NSCLC) – what are the current challenges with treatment? (0:12)
- What evidence already existed on the effect of combining EGFR tyrosine kinase inhibitors and chemotherapy in NSCLC? (1:15)
- Please can you outline the key methodology used in the NVALT 17 study? (2:30)
- How did patients respond in terms of efficacy and safety in the NVALT 17 study? (3:45)
- What are the implications of this study for patients with NSCLC and future research? (4:20)
Disclosures: Rolof Gijtenbeek has nothing to disclose in relation to this video. Presentation slides shared with permission from the author.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
Share this Video
Related Videos In Lung Cancer
A study of varenicline and nicotine replacement therapy for smokers admitted to hospital in Australia: Michael Abramson, ERS 2023
Varenicline was approved as a replacement therapy for smoking back in 2007 in Australia, the uptake for varenicline has remained high despite issues associated with patient adherence and access to the therapy. In this interview, touchRESPIRATORY were delighted to speak with Prof. Michael Abramson (Monash University, Victoria, Australia) to discuss his randomized, placebo-controlled trial evaluating […]
Daniel Steinfort, WCBIP 2022: Findings from the SEISMIC Study
The SEISMIC study investigated lymph nodes by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients with locally advanced non-small cell lung cancer (NSCLC). touchRESPIRATORY were delighted to speak with Dr. Daniel Steinfort (Royal Melbourne Hospital, Melbourne, Australia) to learn more around the aims, design and findings from the study and the importance of these findings […]
Paulo Rodrigues Santos, ERS 2022: Immunosuppressive Factors Affecting Anti-PD-1 Therapy in Phase IIIB/IV Non-small Cell Lung Cancer
touchRESPIRATORY caught up with Dr. Paulo Rodrigues Santos (University of Coimbra, Coimbra, Portugal) to discuss the challenges associated with the use of anti-PD-1 therapy in phase IIIB/IV non-small cell lung cancer, the cellular and plasmatic immunosuppressive factors that affect the outcome of anti-PD-1 therapy and the data supporting the strategies used to overcome these immunosuppressive […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!